A new paradigm for TB drug development is needed—one that focuses on developing not just drugs but entire drug regimens.
The Critical Path to TB Drug Regimens (CPTR) is working to tackle the challenges facing TB drug development. This includes gaining support for a new paradigm of drug development that enables promising combinations of drugs to be tested and developed together to create entirely new multi-drug treatments. This new approach is expected to reduce the time it takes to develop an innovative regimen from decades to years. CPTR is made possible by unprecedented collaboration among pharma companies and strong commitments from public and private partners around the world. More >
Hans-Georg Eichler
FDA approves bedaquiline for TB treatment; first new drug in 40 years
In late December, the US FDA approved bedaquiline for the treatment of MDR-TB on top of the current background regimen. Dr. Chrispin Kambili, an infectious disease specialist at Janssen, recently discussed their research on bedaquiline and reviewed plans for additional research testing on the drug at the 3rd Annual CPTR Workshop this past fall. Bedaquiline is
In October, the Critical Path to TB Drug Regimens (CPTR) initiative convened partners from the academic, foundation, government/regulatory, pharmaceutical and scientific communities in Washington, D.C. for its 3rd Annual Workshop. Participants reviewed individual and collective accomplishments in advancing new TB drug regimen development, as well as the current global and regulatory landscape and other cross-sector
These stories link to the WHO's Working Group on New TB Drugs